Evaluation of Anti-TBGL Antibody in the Diagnosis of Tuberculosis Patients in China
Table 2
Anti-TBGL IgG, anti-TBGL IgA, and anti-LAM IgG in ETB patients.
Subtypes of ETB ()
Number
TB related Biomarkers
Anti-TBGL IgG
Anti-TBGL IgA
Anti-LAM IgG
Tuberculous pleurisy
7
2 (28.6%)a
1.2 [0.4–7.0]b
1 (14.3%)
0.4 [0–4.0]
2 (28.6%)
0.06 [0.02–0.50]
Tuberculous meningitis
4
1 (25%)
0.65 [0.6–8.2]
0 (0%)
0.05 [−0.1–0.7]
1 (25%)
0.05 [0.03–0.08]
Miliary TB
3
2 (66.7%)
2.9 [1.3–5.6]
1 (33.3%)
0.6 [0–2.1]
3 (100%)
0.10 [0.01–0.14]
Intestinal TB
3
3 (100%)
15.9 [3.9–27.9]
1 (33.3%)
1.7 [0.2–428.8]
3 (100%)
0.14 [0.12–0.33]
Lymph node TB
3
1 (33.3%)
0.5 [0.4–11]
0 (0%)
0.2 [0.2–0.2]
2 (66.7%)
0.12 [0.06–0.39]
Renal TB
2
1 (50%)
20.4 [0.3–40.5]
0 (0%)
0.45 [0.2–0.7]
1 (50%)
0.12 [0.06–0.19]
Bone TB
2
1 (50%)
12.85 [0.4–25.3]
0 (0%)
0.2 [0–0.4]
2 (100%)
0.11 [0.10–0.12]
Endometrial TB
1
1 (100%)
3.5 [3.5]
1 (100%)
3.3 [3.3]
0 (0%)
0.06 [0.06]
Extrarenal TB
1
0 (0%)
0.8 [0.8]
0 (0%)
0.1 [0.1]
1 (100%)
0.13 [0.13]
ETB = extrapulmonary TB. apositive number (percentage) in compariso with the cut off of anti-TBGL IgG (cut off = 2), anti-TBGL IgA (cut off = 2), and anti-LAM IgG (cut off = 0.07), respectively; bmedian [range].
